Shoulder Innovations Inc (SI) Q3 2026 Earnings Call Highlights: 38% Revenue Growth

Shoulder Innovations Inc (SI) reported Q3 2026 revenue growth of 38% to $16.2M, driven by a 34% increase in implant systems sold. Gross margin improved to 78.5%. Full-year revenue guidance was raised to $68-$70M. Net loss was $7.0M, and adjusted EBITDA loss was $5.5M. The company expects cash burn to moderately increase in Q4 due to investments in commercial and R&D efforts.

Original reporting
Published Nov 6, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Shoulder Innovations Inc (SI) Q3 2026 Earnings Call Highlights: 38% Revenue Growth — source image
Decision brief

The 30-second read

$SIBullishMed
01

Why it matters

The earnings beat and guidance raise provide a fresh catalyst, while margin expansion expectations may support the stock.

02

Market read

First report of Shoulder Innovations' Q3 results and updated guidance, offering actionable insight for traders.

03

What to watch

Potential regulatory delays for the FDA submission and pricing pressure in ambulatory surgery settings.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Shoulder Innovations Inc. reported its Q3 2026 earnings, showing strong top‑line growth but ongoing losses.

Company-level read

Ticker impact

$SIBullishHigh confidence
Context

Q3 2026 earnings disclosed 38% revenue growth, raised full-year guidance to $68‑$70M, and provided updated margin and cash burn outlook.

Expected impact

likely upward pressure as the market prices in stronger revenue growth and higher guidance

Evidence & confidence

The earnings release contains fresh, material numbers and guidance that were not previously public, providing a clear catalyst for short‑term price movement.

Market effects

Highlights growth potential in the shoulder arthroplasty market, may benefit peers with similar product pipelines.

Limited to U.S. and possibly European orthopedic device markets where the company sells.

Modest; primarily relevant to investors focused on niche medical device stocks.

Counterpoint

Despite revenue growth, continued net losses and rising cash burn could pressure the stock if investors prioritize profitability.

Key entities

  • Rob Ball

    CEO who provided guidance and commentary on growth drivers.

  • Jeff Points

    CFO who detailed financial results and cash position.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.